Human CD30 protein (C-His-Avi) was biotinylated in vitro using BirA ligase. SDS-PAGE analysis under reducing (P+) and non-reducing (P−) conditions shows the protein has a purity greater than 95%. A gel shift assay using co-incubation with streptavidin indicates that the biotinylation efficiency of the CD30 protein exceeds 95%.
Human CD30L (C-His) protein is coated at 1 μg/mL (100ng/well). Biotinylated CD30 (C-His-Avi) can detect the CD30L protein in the dose dependent manner. The ED50 is about 30-100 ng/mL.
Cat #
Size
Price
Quantity
804503
25 ug
$245
804504
100 ug
$595
Product Details
Application
ELISA, BLI
Format
Liquid, Biotinylated
Expression Host
CHO
Target Name
TNFRSF8, CD30, Ki-1
Species
Human
Sources
Recombinant Human CD30 protein (phe19-Lys379) with C-terminus His-Avi tag is expressed in CHO cells. This protein was site-specifically labeled with Biotin by BirA ligase.
accession number
P28908
Molecular Weight
The protein has a predicted molecular weight of 42 kDa. Under DTT-reducing conditions, it migrates at approximately 50-80 kDa on SDS-PAGE.
Affinity Tag
C-His-Avi
Purity
>95% based on SDS-PAGE under reducing condition
Formulation
1xPBS buffer, pH7.4, 0.22 µm filtered
Endotoxin level
Not tested
Protein Concentration
25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
Storage and Handling
Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.
Background Information
CD30, also known as TNFRSF8, is a 120 kDa type I transmembrane glycoprotein from the TNF receptor superfamily. It is expressed on activated T, B, and NK cells, but not resting cells. CD30 is cleaved by metalloproteinases into a soluble form and is highly expressed in classical Hodgkin lymphoma and anaplastic large cell lymphoma. It interacts with proteins like TRAF1, TRAF2, and TRAF5, activating NF-kB signaling. This signaling regulates the proliferative potential of autoreactive CD8 T cells and protects against autoimmunity. CD30 is a therapeutic target in lymphoma immunotherapy and plays a role in autoimmune diseases like rheumatoid arthritis.
Human CD30 protein (C-His-Avi) was biotinylated in vitro using BirA ligase. SDS-PAGE analysis under reducing (P+) and non-reducing (P−) conditions shows the protein has a purity greater than 95%. A gel shift assay using co-incubation with streptavidin indicates that the biotinylation efficiency of the CD30 protein exceeds 95%.
Human CD30L (C-His) protein is coated at 1 μg/mL (100ng/well). Biotinylated CD30 (C-His-Avi) can detect the CD30L protein in the dose dependent manner. The ED50 is about 30-100 ng/mL.
